As part of our ongoing commitment to reliability, accessibility, and quality in the healthcare supply chain, SCA Pharma is pleased to announce an expanded distribution approach for our core pharmaceutical products. Healthcare professionals can now access SCA Pharma’s trusted offerings through a broader network of purchasing platforms, including Medigi as an alternate location. This important…
Product development in 503B outsourcing facilities involves a detailed, highly regulated process. Every compounded medication produced by facilities like SCA Pharma must be safe, compliant, and aligned with the needs of healthcare institutions. This blog dives deeper into the product development process, covering each phase from discovery to post-launch monitoring. The Product Development Process The development…
In the fast-paced healthcare environment, access to critical medications is essential for providing timely, effective patient care. Ensuring the right medications are on hand when needed can be a logistical challenge for hospital pharmacies. This is where a reliable 503B outsourcing facility offering a “Buy & Ship Now” option becomes invaluable. By allowing hospital pharmacies…
Last winter, as the US hospital system became overwhelmed with COVID-19 cases related to the Omicron strain, facilities across the country were forced to postpone elective surgeries to free up hospital beds. Similar to what happened following the initial outbreak of the pandemic in 2020, patients are now returning to the operating room to have…
On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…
SCA Pharma’s customers have requested extended Beyond Use Dating (BUD), and we are pleased to help meet their needs by extending BUDs on 69 products to date, while still maintaining our stringent quality controls. We anticipate extending BUDs on most or all of our products. Beyond Use Dating (BUD) on compounded sterile preparations is important…
This post is our third in a series of blogs looking at how hospitals make the difficult decision to compound their own drugs versus selecting an outsourcing partner. The decision involves a great deal more than a clean room and a vial of medication. A wide range of indirect costs are specifically related to risk…
SCA Pharma is taking a look at how hospitals choose to supply their compounded drug products. Many choose to produce what they need internally – called insourcing – while others use a provider like us – outsourcing. This second blog post in a 3-part series examines the unseen costs of insourcing vs. outsourcing with a…
Hospitals often choose to insource drug compounding in order to save money on Pharmacy costs. The decision to insource is typically based on a number of factors including cost of raw materials and qualified personnel needed to compound the product. We believe that hospitals often fail to include many indirect variables, resulting in under-estimation of…
HCP Roundtable discussion gives SCA Pharma the opportunity to share benefits of partnership with Kit Check.